cropped shot of father holding sons hand in clinic
cropped shot of father holding sons hand in clinic A collaboration of researchers, led by UCL and Great Ormond Street Hospital, have published successful results from a Phase II clinical trial for the treatment of BRAF mutated low-grade paediatric gliomas. Gliomas are cancerous brain tumours that start in glial cells - the supporting cells of the brain. The results from the TADPOLE-G study, published in the New England Journal of Medicine and the Journal of Clinical Oncology , are the first to demonstrate a clear clinical benefit of combining the therapies of Dabrafenib and Trametinib (Novartis) in BRAF mutated lowand high-grade paediatric gliomas respectively. For children with paediatric low-grade gliomas, the normal course of treatment is a full surgical removal. However, for children where this is not possible, additional treatments like chemotherapy are required. These patients often experience multiple relapses, further disease progression and serious side effects. In the randomised trial, 73 children with BRAF mutated low-grade gliomas (BM-LGG) were treated with Dabrafenib and Trametinib.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
